Results 111 to 120 of about 1,292 (153)

Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita. [PDF]

Front Immunol, 2018
Koga H, Kasprick A, López R, Aulí M, Pont M, Godessart N, Zillikens D, Bieber K, Ludwig RJ, Balagué C.   +9 more
europepmc   +1 more source

The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita. [PDF]

J Invest Dermatol, 2017
Németh T, Virtic O, Sitaru C, Mócsai A.   +3 more
europepmc   +1 more source

Steroid-induced Diabetes Complicating Treatment of Epidermolysis Bullosa Acquisita: A Preventable Treatment Complication Stresses the Importance of Primary Care Follow-up. [PDF]

Cureus, 2018
Byrd V, Nemeth A.
europepmc   +1 more source

Accessible Diagnostic Methods to Differentiate between Epidermolysis Bullosa Acquisita and Other Subepidermal Autoimmune Bullous Diseases.

Indian J Dermatol, 2018
Kridin K.
europepmc   +1 more source

Bullous Systemic Lupus Erythematosus as a Marker of Treatment-Refractory Systemic Disease: A Case Report. [PDF]

Cureus
Izadian Bidgoli A, Gomez Veliz A, Mathew J, De Guzman J, Yazdanpanah S, Joshi A.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Epidermolysis Bullosa Acquisita

The American Journal of Dermatopathology, 1988
A case of epidermolysis bullosa acquisita (EBA) occurring in a 30 year-old-farmer is described. Diagnosis was suggested by clinical signs (adult-onset of mechano-bullous lesions healing with atrophic scar and milia formation, in absence of family history, photosensitivity and urine darkening); it was confirmed by laboratory data (normal urinary ...
PISANI M, RUOCCO, Vincenzo, DE ANGELIS E.   +2 more
openaire   +4 more sources

Epidermolysis bullosa acquisita in childhood

Australasian Journal of Dermatology, 1998
SUMMARYThis case report of an 11‐year‐old girl describes a juvenile form of epidermolysis bullosa acquisita, an autoimmune disease of IgG antibodies to basement membrane type 7 collagen. Our case illustrates an unusually severe, acute inflammatory presentation of this condition with prominent mucosal and constitutional features requiring admission to a
J C, Su, G A, Varigos, J, Dowling
openaire   +2 more sources

Colchicine for epidermolysis bullosa acquisita

Journal of the American Academy of Dermatology, 1996
Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is difficult to treat. Recently one patient with severe EBA was described who responded dramatically to colchicine.Our purpose was to determine the efficacy of colchicine in the treatment of EBA.Four patients with severe EBA refractory to conventional therapy were ...
B B, Cunningham, T T, Kirchmann, D, Woodley   +2 more
openaire   +2 more sources

Childhood epidermolysis bullosa acquisita

British Journal of Dermatology, 1994
We report a 6-year-old boy suffering from acquired epidermolysis bullosa, who presented with extensive lesions of the mucous membranes and disseminated, herpetiform and 'cluster of jewels'-like vesicles and bullae arising on erythematous plaques. Direct immunofluorescence showed linear deposits of IgG and C3 at the epidermal basement membrane zone ...
Inauen P, Hunziker T, Gerber H, Bruckner-Tuderman L, Braathen LR   +4 more
openaire   +3 more sources

Pathogenesis of Epidermolysis Bullosa Acquisita

Dermatologic Clinics, 2011
Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen. Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished. Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal.
Ralf J, Ludwig, Detlef, Zillikens
openaire   +2 more sources